Skip to main content
Top
Published in: NanoEthics 1/2014

01-04-2014 | Original Paper

Metaphors in Nanomedicine: The Case of Targeted Drug Delivery

Authors: Bernadette Bensaude Vincent, Sacha Loeve

Published in: NanoEthics | Issue 1/2014

Log in

Activate our intelligent search to find suitable subject content or patents.

search-config
loading …

Abstract

The promises of nanotechnology have been framed by a variety of metaphors, that not only channel the attention of the public, orient the questions asked by researchers, and convey epistemic choices closely linked to ethical preferences. In particular, the image of the ‘therapeutic missile’ commonly used to present targeted drug delivery devices emphasizes precision, control, surveillance and efficiency. Such values are highly praised in the current context of crisis of pharmaceutical innovation where military metaphors foster a general mobilization of resources from multiple fields of cutting-edge research. The missile metaphor, reminiscent of Paul Ehrlich’s ‘magic bullet’, has framed the problem in simple terms: how to deliver the right dose in the right place at the right moment? Chemists, physicists and engineers who design multi-functional devices operating in vitro can think in such terms, as long as the devices are not actually operating through the messy environment of the body. A close look at what has been done and what remains to be done suggests that the metaphor of the “therapeutic missile” is neither sufficient, nor even necessary. Recent developments in nanomedicine suggest that therapeutic efficacy cannot be obtained without negotiating with the biological milieu and taking advantage of what it affords. An ‘oikological’ approach seems more appropriate, more heuristic and more promising than the popular missile. It is based on the view of organism as an oikos that has to be carefully managed. The dispositions of nanocapsules have to be coupled with the affordances of the environment. As it requires dealing with nanoparticles as relational entities (defined by their potential for interactions) rather than as stable substances (defined by intrinsic properties) this metaphor eventually might well change research priorities in nanotechnology in general.

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Footnotes
1
Interviews with Patrick Couvreur (Institut Galien Université Paris-Sud), Florence Gazeau (Laboratoire matière et systèmes complexes, Université Paris Diderot) and Ania Servant (Nanomedicine Laboratory, University College London School of Pharmacy).
 
2
In Rorty’s pragmatic philosophy, language is ‘image-schematic’ but it is not a representational ‘mirror of nature’: it is ‘formative’, i.e.: giving instructions to others about to give form to something, and per-formative, i.e.: being ‘instructive’ in that sense.
 
3
Because all individuals are not responding to the same drug, personalized medicine is looking for molecular signatures—so called ‘biomarkers’—that would allow to direct different categories of patients to more adapted therapies, possibly on the basis of early diagnoses (molecular biomarkers are anything that can be detected and used for measuring the probability of incidence of a disease, its progress, or its treatment’s effects: DNA or RNA single nucleotide polymorphism, protein, complex of proteins, or changes in protein expression).
 
4
Personalized medicine seeks to specify therapy by means of profiling and stratification: It sets up distinct categories of patients with regard to their probability of better responding to this or that therapy on the basis of tests determining the presence of a biomarker. It is to form categories of patients fitting with prescriptions and conversely to adjust prescriptions to categories of patients. Targeted drug delivery, by contrast, starts from a given molecule and a given target (organ, tissue, cell, organelle or molecular receptor) and seeks the most fitting nanoscale formulation to carry the molecule to the target.
 
5
Currently, the innovation landscape of nanovectorization is mostly populated with small start-ups selling their patents to big pharmaceutical companies [77]. They rely on venture capitals and business angels to bear the costs of preclinical development, scaling-up studies, upgrading to legal standards, and phase-I to mid-phase-II trials. Big pharmas cover only end-phase-II and phase III. They adopt a ‘wait-and-see’ strategy ([97]: 4) and refuse to rush head down towards a disruptive technology unless it has pugnaciously proven its safety and efficiency [15].
 
6
It is expected that targeted drug delivery will provide pharmaceutical industry with new patents thanks to the nanoformulation of established molecules before the end period of their IP rights. It also allows patenting older medicines that so far could not enter the market ([4, 97]: 3).
 
7
Here we take the two rival founding fathers as mythical figures. It matters little to us whether Galen and Paracelsus were really what their heirs have made of them. The master narrative built on the two heroes are still framing pharmacological culture.
 
8
Ehrlich wrote that “If we picture an organism as infected by a certain species of bacterium, it will obviously be easy to effect a cure if substances have been discovered which have an exclusive affinity for these bacteria and act deleteriously or lethally on these alone, while at the same time they possess no affinity for the normal constituents of the body and can therefore have the least harmful, or other effect on that body. Such substances would then be able to exert their full action exclusively on the parasite harboured within the organism and would represent, so to speak, magic bullets, which seek their target of their own accord” (Ehrlich [27], p. viii).
 
9
Significantly, twentieth century Galenics refers to the ‘formulation’ of drugs, i.e.: making tablets, suppositories, creams or syrups, according to a specific procedure called a ‘formula’ (a medicinal form suitable for administration). Galenics is often despised by modern pharmacology as being concerned with external form or packaging instead of active principles, as being technique or even marketing, not science—a rather unfair view, since it is Galenics that allows the transformation of a mere ‘drug’ into a proper ‘medicine’. Galenic pharmacy is indeed indispensable for the standardisation of doses and posology as well as for the stabilisation and conservation of active substances [87]. Galenics is the art of taming substances.
 
10
The encapsulation rate is one of the major bottlenecks for the technique. Currently, most systems do not exceed a rate of 10 % of active principles encapsulated on the total amount of nanoparticles synthesized, which limits both their cost-efficiency and therapeutic index.
 
11
Actually, Norbert Wiener’s conceptualization of feedback or retroaction originated in his warfare research on self-guided devices during World War II [32].
 
12
Originally coined to refer to a treatment platform combining a diagnostic test setup with a therapy based on the evolution of the test results [100], theranostic nanomedicine is now defined as ‘an integrated nanotherapeutic system which can diagnose, deliver targeted therapy and monitor the response to therapy’ ([95], p. 137).
 
13
Here, ‘robot’ clearly means an enslaved machine-tool, not an independent automaton. This is not surprising, since, as Nerlich argues [72, 73], the images of nanobots cleaning fats in blood vessels are recycling the older visual archetypes of shrunk humans travelling through the body, as shown in the movie The Fantastic Voyage. Nanomedicine’s imaginary has replaced shrunk surgeons and their tools with miniaturized robots. In turn, the focus has shifted ‘from the “extraordinary” (voyages) to the “ordinary” (medicine), thereby contributing to the normalisation of nanomedicine and its integration into normal biomilitaristic medical discourse’ [74]. The metaphor of the nanorobot has had to be ‘militarized’ to move from pure science fiction to something real, serious, and valued by our society.
 
14
A striking example of fusion between drug and device is the NanoXray™ developed by the French start-up Nanobiotix (http://​www.​youtube.​com/​watch?​v=​kxSX6YJTS2I), in which the nanoparticles amplify the physical mode of action of radiotherapy. NanoXray™ is like a nanoscale extension of the radiotherapy setup internalized in the patient’s body to relay and locally amplify its effect. This conflation is also visible in the normative framework of regulation under which the development of NanoXray™ is placed: under the category ‘drug’ by the US FDA and under the category ‘medical devices’ by the French AFSSAPS. This later regime of regulation would, if not accelerate, at least facilitate NanoXray™’s entrance in the market by bypassing the ever-expanding ‘valley of death’ of pharmaceutical development. As a venture capitalist investing in the start-up put it on one of the Nanobiotix’s site podcasts, ‘I believe we are getting a biotech care company potential with a medical device time-to-market’ (http://​www.​nanobiotix.​com/​about-us/​).
 
15
The nanocarriers obtained by ‘squalenization’ by Couvreur and his team instantiates the identification of the drug with its Galenic formulation. Squalene, a biological organic compound, can chemically bind with the anticancer drug gemcitabin, thus forming a new molecular entity, gemcitabine-squalene, which in turn self-assembles into nanoparticles in water [84].
 
16
On the difference between abstract and concrete engineering views in nanotechnology see [5] 79–82).
 
17
Efficacy is generally defined as the ability to bring about a desired effect, whereas efficiency measures the ratio of beneficial output (e.g.: useful fork, economic profit) versus (the amount of means/resources) involved (time, energy, effort, costs…). Therapeutic efficacy is the main concern in the development process (where it becomes the most important criterion).
 
18
To be sure, military missiles sometimes release munitions without homing devices, at random, in the hope that enemy targets will be affected by statistics. But they don’t have the glamour of surgical strikes.
 
19
Even when the drug carrier is equipped with specific antibodies, peptides or ligands, these so-called ‘homing devices’ do not point only to a target receptor, but also sometimes to a relay receptor enabling the nanovector to cross a biological barrier. For instance, when decorated with the specific antibody of the transferrin receptor, chitosan nanospheres can cross the blood–brain barrier for delivering biologically peptides to the brain [52]. In this case, a temporary alliance is contracted with a smuggler afforded by a particular biological milieu.
 
20
Enhanced Permeability and Retention is the effect of inflammation, which induces the arrival of macrophages and the release of cytokines increasing the permeability of vessels.
 
21
This is the case of the palmarplantar erythrodysesthesia or ‘hand-foot syndrome’. Hands and feet are usually subjected to mechanical pressure and friction, which causes instantaneous dilatation of the endothelial tissue of blood vessels which, similarly to the EPR effect. Yet this allows the nanocarriers to locally cross the endothelial wall of healthy tissues. The areas affected become red, dry, peel, numb or painful, with possible necrosis. This unwanted leakage of the nanocarrier can be attenuated by modifying some everyday activities (avoiding wearing tight clothes, using tools, jogging, taking hot showers or being exposed to strong sunlight). But for very sensitive patients such an adverse effect unfortunately limits the maximal safe Doxil® dose that can be administrated as compared with doxorubicin in the same treatment regime.
 
22
For this purpose, lentil-shaped liposomes were designed to release their content only under the high shear stress found in constricted blood vessels [47, 56].
 
23
To attribute a dispositional property to a thing amounts to saying that if certain conditions are obtained, then that thing will behave in a specific manner or bring about a specific effect. For instance ’a negatively charged particle is one of which it is true that, if brought into proximity to another negatively charged particle, it will experience a force of repulsion’ ([41], p. 97).
 
24
The term affordance coined by James J. Gibson in the context of animal psychology combines generic material dispositions and specific intentions and purposes. In Gibson’s ecological theory of perception, affordances are the possibilities of action that are offered to an agent by an environment [38]. The concept has also been used in design theory, to express how objects invite and constrain their users by offering ‘cues for action’ [23, 76].
 
Literature
1.
go back to reference Annas G (1995) Reframing the debate on health care reform by replacing our metaphors. N Engl J Med 332:744–747CrossRef Annas G (1995) Reframing the debate on health care reform by replacing our metaphors. N Engl J Med 332:744–747CrossRef
2.
go back to reference Arrigo BA (1999) Martial metaphors and medical justice: implications for law, crime, and deviance. J Polit Mil Soc 27:307–322CrossRef Arrigo BA (1999) Martial metaphors and medical justice: implications for law, crime, and deviance. J Polit Mil Soc 27:307–322CrossRef
3.
go back to reference Austin JL (1962) How to do things with words. Clarendon, Oxford Austin JL (1962) How to do things with words. Clarendon, Oxford
4.
go back to reference Bawa R (2008) Nanoparticle-based therapeutics in humans: a survey. Nanotechnol Law Bus 5:135–155 Bawa R (2008) Nanoparticle-based therapeutics in humans: a survey. Nanotechnol Law Bus 5:135–155
5.
go back to reference Bensaude-Vincent B, Guchet X (2007) Nanomachine: One Word for Three Different Paradigms. Technè 11:71–89. Bensaude-Vincent B, Guchet X (2007) Nanomachine: One Word for Three Different Paradigms. Technè 11:71–89.
7.
go back to reference Boenink M (2009) Tensions and opportunities in convergence: shifting concepts of disease in emerging molecular medicine. Nanoethics 3:243–255CrossRef Boenink M (2009) Tensions and opportunities in convergence: shifting concepts of disease in emerging molecular medicine. Nanoethics 3:243–255CrossRef
8.
go back to reference Caroll SP (2011) Conciliation biology: the eco-evolutionary management of permanently invaded biotic systems. Evol Appl 4:184–199CrossRef Caroll SP (2011) Conciliation biology: the eco-evolutionary management of permanently invaded biotic systems. Evol Appl 4:184–199CrossRef
9.
go back to reference Chauhan VP, Stylianopoulos T, Martin JD, Popovic Z, Chen O, Kamoun WS, Bawendi MG, Fukumura D, Jain RK (2012) Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 7:383–388CrossRef Chauhan VP, Stylianopoulos T, Martin JD, Popovic Z, Chen O, Kamoun WS, Bawendi MG, Fukumura D, Jain RK (2012) Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 7:383–388CrossRef
10.
go back to reference Cheng Z, Zaki AA, Hui JZ, Muzykantov VR, Tsourkas A (2012) Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 338:903–910CrossRef Cheng Z, Zaki AA, Hui JZ, Muzykantov VR, Tsourkas A (2012) Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 338:903–910CrossRef
11.
13.
go back to reference Choi WI, Kim JY, Kang C, Byeon CC, Kim YH, Tae G (2011) Tumor regression in vivo by photothermal therapy based on gold-nanorod-loaded, functional nanocarriers. ACS Nano 5:1995–2003CrossRef Choi WI, Kim JY, Kang C, Byeon CC, Kim YH, Tae G (2011) Tumor regression in vivo by photothermal therapy based on gold-nanorod-loaded, functional nanocarriers. ACS Nano 5:1995–2003CrossRef
15.
go back to reference Couvreur P (2010) Interview by Xavier Guchet, Sacha Loeve & Nicolas Sauret, Faculté de pharmacie de Chatenay-Malabry, 30 November 2010 Couvreur P (2010) Interview by Xavier Guchet, Sacha Loeve & Nicolas Sauret, Faculté de pharmacie de Chatenay-Malabry, 30 November 2010
16.
go back to reference Couvreur P, Kante B, Grislain L, Roland M, Speiser P (1982) Toxicity of polyalkylcyanoacrylate nanoparticles II: doxorubicin-loaded nanoparticles. J Pharm Sci 71:1520–6017CrossRef Couvreur P, Kante B, Grislain L, Roland M, Speiser P (1982) Toxicity of polyalkylcyanoacrylate nanoparticles II: doxorubicin-loaded nanoparticles. J Pharm Sci 71:1520–6017CrossRef
17.
go back to reference Couvreur P, Tulkens P, Roland M, Trouet A, Speiser P (1977) Nanocapsules: a new type of lysosomotropic carrier. FEBS Lett 84:323–326CrossRef Couvreur P, Tulkens P, Roland M, Trouet A, Speiser P (1977) Nanocapsules: a new type of lysosomotropic carrier. FEBS Lett 84:323–326CrossRef
18.
go back to reference Couvreur P, Vauthier C (2006) Nanotechnology. Intelligent design to treat complex disease. Pharm Res 23:1417–1450CrossRef Couvreur P, Vauthier C (2006) Nanotechnology. Intelligent design to treat complex disease. Pharm Res 23:1417–1450CrossRef
20.
go back to reference De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke JPM, Schroeder TV, Sox HC, Van Der Weyden MB (2004) Clinical trial registration: a statement from the International Committee of Medical Journal Editors. J Am Med Assoc 1671:137–141 De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke JPM, Schroeder TV, Sox HC, Van Der Weyden MB (2004) Clinical trial registration: a statement from the International Committee of Medical Journal Editors. J Am Med Assoc 1671:137–141
21.
go back to reference Debus AG (1991) The French Paracelsians. the chemical challenge to the medical and scientific tradition in early modern France. Cambridge University Press, Cambridge Debus AG (1991) The French Paracelsians. the chemical challenge to the medical and scientific tradition in early modern France. Cambridge University Press, Cambridge
22.
go back to reference Debus AG (1993) Paracelsus and the medical revolution of the renaissance; a 500th anniversary celebration. In: Debus AG (ed) Paracelsus, five hundred years; three american exhibits. National Library of Medicine, Washington, DC, p 3 Debus AG (1993) Paracelsus and the medical revolution of the renaissance; a 500th anniversary celebration. In: Debus AG (ed) Paracelsus, five hundred years; three american exhibits. National Library of Medicine, Washington, DC, p 3
23.
24.
go back to reference DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development cost. J Health Econ 22:151–185CrossRef DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development cost. J Health Econ 22:151–185CrossRef
25.
go back to reference Downing GJ (2009) Key aspects of heath care on the path to personalized medicine. Transl Res 154:272–276CrossRef Downing GJ (2009) Key aspects of heath care on the path to personalized medicine. Transl Res 154:272–276CrossRef
26.
go back to reference Drews J (2000) Drug discovery: a historical perspective. Science 287:1960–1964CrossRef Drews J (2000) Drug discovery: a historical perspective. Science 287:1960–1964CrossRef
27.
go back to reference Ehrlich P ([1906] 1960) Address delivered at the dedication of the Georg-Speyer-Haus. In: Himmelweit F (ed) The collected papers of Paul Ehrlich. Pergamon Press, London, pp 53–63 Ehrlich P ([1906] 1960) Address delivered at the dedication of the Georg-Speyer-Haus. In: Himmelweit F (ed) The collected papers of Paul Ehrlich. Pergamon Press, London, pp 53–63
28.
go back to reference Fox Keller E (1992) Secrets of life, secrets of death: essays on language, gender and science. Routledge, New York Fox Keller E (1992) Secrets of life, secrets of death: essays on language, gender and science. Routledge, New York
29.
go back to reference Fox Keller E (1995) Refiguring life: metaphors of twentieth-century biology. Columbia University Press, New York Fox Keller E (1995) Refiguring life: metaphors of twentieth-century biology. Columbia University Press, New York
30.
go back to reference Fox Keller E (2002) Making sense of life: explaining biological development with models, metaphors, and machines. Harvard University Press, Harvard Fox Keller E (2002) Making sense of life: explaining biological development with models, metaphors, and machines. Harvard University Press, Harvard
31.
go back to reference Gabizon AA (2001) Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res 7:243–254 Gabizon AA (2001) Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res 7:243–254
32.
go back to reference Galison P (1994) The ontology of the enemy: Norbert Wiener and the cybernetic vision. Crit Inq 21:228–266CrossRef Galison P (1994) The ontology of the enemy: Norbert Wiener and the cybernetic vision. Crit Inq 21:228–266CrossRef
33.
34.
go back to reference Gatenby RA (2009) A change of strategy in the war on cancer. Nature 459:508–509CrossRef Gatenby RA (2009) A change of strategy in the war on cancer. Nature 459:508–509CrossRef
35.
go back to reference Gatenby RA, Brown J, Vincent T (2009) Lessons from applied ecology: cancer control using an evolutionary double bind. Cancer Res 69:7499–7502CrossRef Gatenby RA, Brown J, Vincent T (2009) Lessons from applied ecology: cancer control using an evolutionary double bind. Cancer Res 69:7499–7502CrossRef
36.
go back to reference Gatenby RA, Silva AS, Gillies RJ, Frieden BR (2009) Adaptive therapy. Cancer Res 69:4894–4903CrossRef Gatenby RA, Silva AS, Gillies RJ, Frieden BR (2009) Adaptive therapy. Cancer Res 69:4894–4903CrossRef
37.
go back to reference Gazeau F (2011) Interview by B. Bensaude Vincent, Université Paris-Diderot, 29 November 2011 Gazeau F (2011) Interview by B. Bensaude Vincent, Université Paris-Diderot, 29 November 2011
38.
go back to reference Gibson JJ (1979) The ecological approach to visual perception. Houghton Mifflin, Boston Gibson JJ (1979) The ecological approach to visual perception. Houghton Mifflin, Boston
39.
go back to reference Goldacre B (2012) Bad Pharma: how drug companies mislead doctors and harm patients. Fourth Estate, London Goldacre B (2012) Bad Pharma: how drug companies mislead doctors and harm patients. Fourth Estate, London
41.
go back to reference Harré R (2001) Dispositions and powers. In: Newton-Smith WH (ed) A companion to the philosophy of science. Blackwell Companions to Philosophy, Blackwell Publishers, Oxford, pp 97–101 Harré R (2001) Dispositions and powers. In: Newton-Smith WH (ed) A companion to the philosophy of science. Blackwell Companions to Philosophy, Blackwell Publishers, Oxford, pp 97–101
42.
go back to reference Harré R (2003) The materiality of instruments in a metaphysics for experiments. In: Radder H (ed) Philosophy of scientific experimentation. University of Pittsburgh Press, Pittsburgh, pp 19–38 Harré R (2003) The materiality of instruments in a metaphysics for experiments. In: Radder H (ed) Philosophy of scientific experimentation. University of Pittsburgh Press, Pittsburgh, pp 19–38
43.
go back to reference Henderson M (2009) New attack on cancer with nano-weapon. The Times, London, p 3 Henderson M (2009) New attack on cancer with nano-weapon. The Times, London, p 3
44.
go back to reference Hillaireau H, Couvreur P (2009) Nanocarriers’ entry into the cell: relevance to drug delivery. Cell Mol Life Sci 66:2873–2896CrossRef Hillaireau H, Couvreur P (2009) Nanocarriers’ entry into the cell: relevance to drug delivery. Cell Mol Life Sci 66:2873–2896CrossRef
45.
go back to reference Hoffman AS (2008) The origins and evolution of ‘controlled’ drug delivery systems. J Control Release 132:153–163CrossRef Hoffman AS (2008) The origins and evolution of ‘controlled’ drug delivery systems. J Control Release 132:153–163CrossRef
46.
go back to reference Hofmann B (2001) The technological invention of disease. Med Humanit 27:10–19CrossRef Hofmann B (2001) The technological invention of disease. Med Humanit 27:10–19CrossRef
47.
go back to reference Holme NM, Fedotenko AI, Abegg D, Althaus J, Babel L, Favarger F, Reiter R, Tanasescu R, Zaffalon P-L, Ziegler A, Müller B, Saxer T, Zumbuehl A (2012) Shear-stress sensitive lenticular vesicles for targeted drug delivery. Nat Nanotechnol 7:536–543CrossRef Holme NM, Fedotenko AI, Abegg D, Althaus J, Babel L, Favarger F, Reiter R, Tanasescu R, Zaffalon P-L, Ziegler A, Müller B, Saxer T, Zumbuehl A (2012) Shear-stress sensitive lenticular vesicles for targeted drug delivery. Nat Nanotechnol 7:536–543CrossRef
48.
go back to reference Jain KK (2005) Role of nanobiotechnology in developing personalized medicine for cancer. Technol Cancer Res Treat 4:645–650 Jain KK (2005) Role of nanobiotechnology in developing personalized medicine for cancer. Technol Cancer Res Treat 4:645–650
49.
go back to reference Jain RK, Stylianopoulos T (2010) Delivering nanomedicines to solid tumors. Nat Rev Clin Oncol 11:653–664CrossRef Jain RK, Stylianopoulos T (2010) Delivering nanomedicines to solid tumors. Nat Rev Clin Oncol 11:653–664CrossRef
50.
go back to reference Jones R (2004) Soft machines. Nanotechnology and life. Oxford University Press, Oxford Jones R (2004) Soft machines. Nanotechnology and life. Oxford University Press, Oxford
52.
go back to reference Karatas H, Aktas Y, Gursoy-Ozdemir Y, Bodur E, Yemisci M, Caban S, Vural A, Pinarbasli O, Capan Y, Fernandez-Megia E, Novoa-Carballal R, Riguera R, Andrieux K, Couvreur P, Dalkara T (2009) A nanomedicine transports a peptide caspase-3 inhibitor across the blood–brain barrier and provides neuroprotection. J Neurosci 29:13761–13769CrossRef Karatas H, Aktas Y, Gursoy-Ozdemir Y, Bodur E, Yemisci M, Caban S, Vural A, Pinarbasli O, Capan Y, Fernandez-Megia E, Novoa-Carballal R, Riguera R, Andrieux K, Couvreur P, Dalkara T (2009) A nanomedicine transports a peptide caspase-3 inhibitor across the blood–brain barrier and provides neuroprotection. J Neurosci 29:13761–13769CrossRef
53.
go back to reference Kopf H (1975) Charakterisierung, anwendung und eignung der Nanokapsulierung auf acrylamidbasis, zur einhüllung niedermolekolarer arzneistoffe. Dissertation n° 5458, ETH Zürich Kopf H (1975) Charakterisierung, anwendung und eignung der Nanokapsulierung auf acrylamidbasis, zur einhüllung niedermolekolarer arzneistoffe. Dissertation n° 5458, ETH Zürich
54.
go back to reference Kopf H, Joshi RK, Soliva M, Speiser P (1976) Studium der Mizellpolymerisation in Gegenwart niedermolekularer Arzneistoffe. 1: Herstellung und Isolierung der Nanopartikel, Restmonomeren-bestimmung, physikalisch-chemische Daten. Pharm Ind 38:281–284 Kopf H, Joshi RK, Soliva M, Speiser P (1976) Studium der Mizellpolymerisation in Gegenwart niedermolekularer Arzneistoffe. 1: Herstellung und Isolierung der Nanopartikel, Restmonomeren-bestimmung, physikalisch-chemische Daten. Pharm Ind 38:281–284
55.
go back to reference Kopf H, Joshi RK, Soliva M, Speiser P (1977) Studium der Mizellpolymerisation in Gegenwart niedermolekularer Arzneistoffe. 2: Bindungsart von inkorporierten niedermolekularen Modellarzneistoffen an Nanopartikel auf Polyacrylamid-Basis. Restmonomerenbestimmung, physikalisch-chemische Daten. Pharm Ind 39:993–997 Kopf H, Joshi RK, Soliva M, Speiser P (1977) Studium der Mizellpolymerisation in Gegenwart niedermolekularer Arzneistoffe. 2: Bindungsart von inkorporierten niedermolekularen Modellarzneistoffen an Nanopartikel auf Polyacrylamid-Basis. Restmonomerenbestimmung, physikalisch-chemische Daten. Pharm Ind 39:993–997
56.
go back to reference Korin N, Kanapathipillai M, Matthews BD, Crescente M, Brill A, Mammoto T, Ghosh K, Jurek S, Bencherif SA, Bhatta D, Coskun AU, Feldman CL, Wagner DD, Ingber DE (2012) Shear-activated nanotherapeutics for drug targeting to obstructed blood vessels. Science 337:738–742CrossRef Korin N, Kanapathipillai M, Matthews BD, Crescente M, Brill A, Mammoto T, Ghosh K, Jurek S, Bencherif SA, Bhatta D, Coskun AU, Feldman CL, Wagner DD, Ingber DE (2012) Shear-activated nanotherapeutics for drug targeting to obstructed blood vessels. Science 337:738–742CrossRef
57.
go back to reference Kramer PA (1974) Albumin microspheres as vehicles for achieving specificity in drug delivery. J Pharm Sci 63:1646–1647CrossRef Kramer PA (1974) Albumin microspheres as vehicles for achieving specificity in drug delivery. J Pharm Sci 63:1646–1647CrossRef
58.
go back to reference Kwon IK, Lee SC, Han B, Park K (2012) Analysis of the current status of targeted drug delivery to tumors. J Control Release 164:108–114CrossRef Kwon IK, Lee SC, Han B, Park K (2012) Analysis of the current status of targeted drug delivery to tumors. J Control Release 164:108–114CrossRef
59.
go back to reference Lakoff G, Johnson M (1980) Metaphors we live by. University of Chicago Press, Chicago Lakoff G, Johnson M (1980) Metaphors we live by. University of Chicago Press, Chicago
61.
go back to reference Loeve S, Normand M (2011) How to trust a molecule? The case of cyclodextrins entering the nanorealm. In: Zülsdorf TB, Coenen C, Fiedeler U, Ferrari A, Milburn C, Wienroth M (eds) Quantum engagements. Social reflections of nanoscience and emerging technologies. IOS Press/AKA Verlag, Heidelberg, pp 195–217 Loeve S, Normand M (2011) How to trust a molecule? The case of cyclodextrins entering the nanorealm. In: Zülsdorf TB, Coenen C, Fiedeler U, Ferrari A, Milburn C, Wienroth M (eds) Quantum engagements. Social reflections of nanoscience and emerging technologies. IOS Press/AKA Verlag, Heidelberg, pp 195–217
62.
go back to reference Maasen S, Weingart P (2000) Metaphors and the dynamics of knowledge. Routledge, London Maasen S, Weingart P (2000) Metaphors and the dynamics of knowledge. Routledge, London
63.
go back to reference Manish G, Vimukta S (2011) Targeted drug delivery system: a review. Res J Chem Sci 1:135–138 Manish G, Vimukta S (2011) Targeted drug delivery system: a review. Res J Chem Sci 1:135–138
64.
go back to reference Marty JJ (1977) The preparation, purification, and properties of nanoparticles. Dissertation, Victorian College of Pharmacy, Parksville, Australia Marty JJ (1977) The preparation, purification, and properties of nanoparticles. Dissertation, Victorian College of Pharmacy, Parksville, Australia
65.
go back to reference Marty JJ, Oppenheim RC, Speiser P (1978) Nanoparticles—a new colloidal drug delivery system. Pharm Acta Helv 53:17–23 Marty JJ, Oppenheim RC, Speiser P (1978) Nanoparticles—a new colloidal drug delivery system. Pharm Acta Helv 53:17–23
66.
go back to reference Merlo LM, Pepper JW, Reid BJ, Maley CC (2006) Cancer as an evolutionary and ecological process. Nat Rev Cancer 6:924–935CrossRef Merlo LM, Pepper JW, Reid BJ, Maley CC (2006) Cancer as an evolutionary and ecological process. Nat Rev Cancer 6:924–935CrossRef
67.
go back to reference Montgomery SL (1991) Codes and combat in biomedical discourse. Sci Cult 2:341–391CrossRef Montgomery SL (1991) Codes and combat in biomedical discourse. Sci Cult 2:341–391CrossRef
68.
go back to reference Montgomery SL (1996) The scientific voice. Guilford Press, New York Montgomery SL (1996) The scientific voice. Guilford Press, New York
69.
go back to reference Morris MC (2012) Cancer et nanotechnologie. Innovation en diagnostic, vectorisation et thérapeutique. Rayonnement CNRS 58:47–57 Morris MC (2012) Cancer et nanotechnologie. Innovation en diagnostic, vectorisation et thérapeutique. Rayonnement CNRS 58:47–57
70.
go back to reference Munos B (2009) Lessons for 60 years of pharmaceutical innovation. Nat Rev Drug Discov 8:959–968CrossRef Munos B (2009) Lessons for 60 years of pharmaceutical innovation. Nat Rev Drug Discov 8:959–968CrossRef
73.
go back to reference Nerlich B (2008) Powered by imagination: nanobots at the science photo library. Sci Cult 17:269–292CrossRef Nerlich B (2008) Powered by imagination: nanobots at the science photo library. Sci Cult 17:269–292CrossRef
76.
go back to reference Norman DA (1990) The design of everyday things. Doubleday, New York Norman DA (1990) The design of everyday things. Doubleday, New York
79.
go back to reference Park K (2007) Nanotechnology: what it can do for drug delivery. J Control Release 120:1–3CrossRef Park K (2007) Nanotechnology: what it can do for drug delivery. J Control Release 120:1–3CrossRef
81.
go back to reference Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL (2010) How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 9:203–214 Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL (2010) How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 9:203–214
83.
go back to reference Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WCW (2009) Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett 9:1909–1915CrossRef Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WCW (2009) Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett 9:1909–1915CrossRef
84.
go back to reference Pili B, Bourgaux C, Amenitsch H, Keller G, Lepêtre-Mouelhi S, Desmaële D, Couvreur P, Ollivon M (2010) Interaction of a new anticancer prodrug, gemcitabine-squalene, with a model membrane: coupled DSC and XRD study. Biochim Biophys Acta 1798:1522–1532CrossRef Pili B, Bourgaux C, Amenitsch H, Keller G, Lepêtre-Mouelhi S, Desmaële D, Couvreur P, Ollivon M (2010) Interaction of a new anticancer prodrug, gemcitabine-squalene, with a model membrane: coupled DSC and XRD study. Biochim Biophys Acta 1798:1522–1532CrossRef
85.
go back to reference Pillai O, Dhanikula AB, Panchagnula R (2008) Drug delivery: an Odyssey of 100 years. Curr Opin Chem Biol 5:439–446CrossRef Pillai O, Dhanikula AB, Panchagnula R (2008) Drug delivery: an Odyssey of 100 years. Curr Opin Chem Biol 5:439–446CrossRef
86.
go back to reference Rai MK, Deshmukh SD, Ingle AP, Gade AK (2012) Silver nanoparticles: the powerful nanoweapon against multidrug-resistant bacteria. J Appl Microbiol 112:841–852CrossRef Rai MK, Deshmukh SD, Ingle AP, Gade AK (2012) Silver nanoparticles: the powerful nanoweapon against multidrug-resistant bacteria. J Appl Microbiol 112:841–852CrossRef
87.
go back to reference Rasmussen A (2005) Préparer, produire, présenter des agents thérapeutiques. Histoires de l’objet médicament. In: Bonah C, Rasmussen A (eds) Histoire et médicament aux XIXe et XXe siècles. Éditions Glyphe, Paris, pp 159–188 Rasmussen A (2005) Préparer, produire, présenter des agents thérapeutiques. Histoires de l’objet médicament. In: Bonah C, Rasmussen A (eds) Histoire et médicament aux XIXe et XXe siècles. Éditions Glyphe, Paris, pp 159–188
88.
go back to reference Rorty R (1979) Philosophy and the mirror of nature. Princeton University Press, Princeton Rorty R (1979) Philosophy and the mirror of nature. Princeton University Press, Princeton
89.
go back to reference Rossi MA (2012) Targeting anti-epileptic drug therapy without collateral damage: nanocarrier-based drug delivery. Epilepsy Currents 12:199–200CrossRef Rossi MA (2012) Targeting anti-epileptic drug therapy without collateral damage: nanocarrier-based drug delivery. Epilepsy Currents 12:199–200CrossRef
90.
go back to reference Sano K, Nakajima T, Choyke PL, Kobayashi H (2013) Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors. ACS Nano 7:717–724CrossRef Sano K, Nakajima T, Choyke PL, Kobayashi H (2013) Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors. ACS Nano 7:717–724CrossRef
91.
go back to reference Shakeri-Zadeh A, Ali Mansoori G, Reza Hashemian A, Eshghi H, Sazgarnia A, Reza Montazebadi A (2010) Cancerous cells targeting and destruction using folate conjugated gold nanoparticles. Dyn Biochem Process Biotechnol Mol Biol 4:6–12 Shakeri-Zadeh A, Ali Mansoori G, Reza Hashemian A, Eshghi H, Sazgarnia A, Reza Montazebadi A (2010) Cancerous cells targeting and destruction using folate conjugated gold nanoparticles. Dyn Biochem Process Biotechnol Mol Biol 4:6–12
92.
go back to reference Simondon G (1958) Du mode d’existence des objets techniques, 2nd edn. Aubier, Paris Simondon G (1958) Du mode d’existence des objets techniques, 2nd edn. Aubier, Paris
94.
go back to reference Strebhardt K, Ullrich A (2008) Timeline: Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer 8:473–480CrossRef Strebhardt K, Ullrich A (2008) Timeline: Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer 8:473–480CrossRef
95.
go back to reference Sumer B, Gao J (2008) Theranostic nanomedicine for cancer. Nanomedicine 3:137–140CrossRef Sumer B, Gao J (2008) Theranostic nanomedicine for cancer. Nanomedicine 3:137–140CrossRef
96.
go back to reference Swinney DC, Anthony J (2011) How were new medicines discovered? Nat Rev Drug Discov 10:507–519CrossRef Swinney DC, Anthony J (2011) How were new medicines discovered? Nat Rev Drug Discov 10:507–519CrossRef
97.
go back to reference Te Kulve H, Rip A (2013) Societal and economic dimensions of nano-enabled drug delivery. Expert Opin Drug Deliv 10:611–622CrossRef Te Kulve H, Rip A (2013) Societal and economic dimensions of nano-enabled drug delivery. Expert Opin Drug Deliv 10:611–622CrossRef
98.
go back to reference Tiwari PM, Vig K, Dennis VA, Singh SR (2011) Functionalized gold nanoparticles and their biomedical applications. Nanomaterials 1:31–63CrossRef Tiwari PM, Vig K, Dennis VA, Singh SR (2011) Functionalized gold nanoparticles and their biomedical applications. Nanomaterials 1:31–63CrossRef
99.
go back to reference Wagner V, Dullaart A, Bock A-K, Zweck A (2006) The emerging nanomedicine landscape. Nat Nanotechnol 24:1211–1217 Wagner V, Dullaart A, Bock A-K, Zweck A (2006) The emerging nanomedicine landscape. Nat Nanotechnol 24:1211–1217
100.
go back to reference Warner S (2004) Diagnostics plus therapy = theranostics. Scientist 18:38–39 Warner S (2004) Diagnostics plus therapy = theranostics. Scientist 18:38–39
101.
go back to reference Wong C, Stylianopoulos T, Cui J, Martin J, Chauhan VP, Jiang W, Popović Z, Jain RK, Bawendi MG, Fukumura D (2011) Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci 108:2426–2431CrossRef Wong C, Stylianopoulos T, Cui J, Martin J, Chauhan VP, Jiang W, Popović Z, Jain RK, Bawendi MG, Fukumura D (2011) Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci 108:2426–2431CrossRef
Metadata
Title
Metaphors in Nanomedicine: The Case of Targeted Drug Delivery
Authors
Bernadette Bensaude Vincent
Sacha Loeve
Publication date
01-04-2014
Publisher
Springer Netherlands
Published in
NanoEthics / Issue 1/2014
Print ISSN: 1871-4757
Electronic ISSN: 1871-4765
DOI
https://doi.org/10.1007/s11569-013-0183-5

Other articles of this Issue 1/2014

NanoEthics 1/2014 Go to the issue

Critical Discussion Notes

Artificial Life and Ethics

Premium Partner